TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38598227

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (100 impulses of 0.1mJ/mm/cm2 in gastrocnemius muscle, 3 times weekly for 3 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo therapy (no shockwaves delivered)
Number of subjects: 138
Study: 38598229

Group type: EXPERIMENTAL
Intervention: Guselkumab (subcutaneous injections at FDA-approved dosing schedule for psoriasis over 24 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 14
Study: 38598401

Group type: EXPERIMENTAL
Intervention: ROBOT group (SAR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: COMPUTER group
Number of subjects: 33

Group type: COMPARATOR
Intervention: CONTROL group
Number of subjects: 33
Study: 38598511

Group type: EXPERIMENTAL
Intervention: Informational handout accompanying LCS results delivery
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standardized form letter of LCS results
Number of subjects: 389
Study: 38598516

Group type: EXPERIMENTAL
Intervention: Parsaclisib + rituximab (Treatment A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parsaclisib + rituximab + bendamustine (Treatment B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parsaclisib + ibrutinib (Treatment C)
Number of subjects: 50
Study: 38598573

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study: 38598571

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy only
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Completion axillary-lymph-node dissection
Number of subjects: 2766
Study: 38598574

Group type: EXPERIMENTAL
Intervention: Personalized algorithm intervention using electronic health records (EHR) and practice facilitators
Number of subjects: 11182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11182

Group type: EXPERIMENTAL
Intervention: Personalized algorithm intervention
Number of subjects: 11182
Study: 38598572

Group type: EXPERIMENTAL
Intervention: Lixisenatide (daily subcutaneous for 12 months)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (daily for 12 months)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lixisenatide (after 2-month washout)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (after 2-month washout)
Number of subjects: 156
Study: 38598710

Group type: EXPERIMENTAL
Intervention: Myeloablative consolidation with thiotepa plus carmustine and autologous stem cell rescue
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonmyeloablative consolidation with infusional etoposide plus cytarabine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Myeloablative consolidation (for those who completed therapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonmyeloablative consolidation (for those who completed therapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonmyeloablative arm during induction
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Myeloablative arm during induction
Number of subjects: 113
Study: 38598745

Group type: EXPERIMENTAL
Intervention: Acalabrutinib plus obinutuzumab
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Zanubrutinib
Number of subjects: 566
Study: 38598794

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 257

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 257
Study: 38598795

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical removal of the hematoma plus guideline-based medical management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Guideline-based medical management alone
Number of subjects: 300
Study: 38598898

Group type: EXPERIMENTAL
Intervention: DrinksRation (28-day smartphone-based alcohol intervention)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 123
Study: 38598970

Group type: EXPERIMENTAL
Intervention: Patients with concomitant peripheral arterial disease (PADs)
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Patients without concomitant peripheral arterial disease (PADs)
Number of subjects: 2705
Study: 38599161

Group type: EXPERIMENTAL
Intervention: pEEG-guided general anesthesia
Number of subjects: 110

Group type: COMPARATOR
Intervention: non-pEEG-guided general anesthesia
Number of subjects: 110
Study: 38599184

Group type: EXPERIMENTAL
Intervention: Contemporary care for ACS patients
Number of subjects: 2463
Study: 38599207

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in normal eyes (AREDS classification)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in early AMD (eAMD) eyes (AREDS classification)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in intermediate AMD (iAMD) eyes (AREDS classification)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in normal eyes (Beckman classification)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in early AMD (eAMD) eyes (Beckman classification)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: qAF8 measurement in intermediate AMD (iAMD) eyes (Beckman classification)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Comparison of qAF8 among diagnostic groups
Number of subjects: 346
Study: 38599220

Group type: COMPARATOR
Intervention: Ticagrelor plus placebo
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 3400
Study: 38599221

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study: 38599257

Group type: EXPERIMENTAL
Intervention: Technology-assisted Web App for self-selection of nonprescription statin treatment
Number of subjects: 1196
Study: 38599522

Group type: EXPERIMENTAL
Intervention: Plant-Based Meat Analogs (PBMD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Animal-Based Meat Diet (ABMD)
Number of subjects: 89
Study: 38599653

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccines in IMIDs patients
Number of subjects: 2079

Group type: COMPARATOR
Intervention: SARS-CoV-2 vaccines in healthy controls (HC)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Post-immunisation anti-RBD levels <6000 binding antibody units/mL
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Hybrid immunity
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Vaccinated patients with IMID
Number of subjects: 2079
Study: 38599690

Group type: EXPERIMENTAL
Intervention: MViR with third-generation balloon-expandable aortic transcatheter heart valves
Number of subjects: 820
Study: 38599711

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 4617

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 4617
Study: 38599715

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 38599799

Group type: EXPERIMENTAL
Intervention: Maternal medicines
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBPK models
Number of subjects: 15
Study: 38599800

Group type: EXPERIMENTAL
Intervention: Weekly oral administration of 10,000 IU vitamin D
Number of subjects: 1682

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1682
Study: 38599894

Group type: EXPERIMENTAL
Intervention: Fosgonimeton or its active metabolite, fosgo-AM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Aβ challenged neurons without treatment)
Number of subjects: 0
Study: 38599907

Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion (FETO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Expectantly managed CDH patients (Control)
Number of subjects: 18
Study: 38600065

Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD, Prolon®)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Glycocalyx mimetic supplementation (Endocalyx)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study: 38600074

Group type: EXPERIMENTAL
Intervention: ROBERT robotic technology, 60 repetitions of hip flexion in supine, supervised by one physiotherapist, active exercise time varied from 7.5 to 17 minutes.
Number of subjects: 4
Study: 38600099

Group type: EXPERIMENTAL
Intervention: Patients recovered from COVID-19
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Molecular profiling analysis of blood plasma
Number of subjects: 40
Study: 38600117

Group type: EXPERIMENTAL
Intervention: dACC Glx
Number of subjects: 70

Group type: COMPARATOR
Intervention: Positive and negative FC of DMN, DAN, and ECN
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Higher-order resting state networks
Number of subjects: 70
Study: 38600278

Group type: EXPERIMENTAL
Intervention: High antihypertensive medication burden (≥3 different classes of prescribed antihypertensive medications)
Number of subjects: 8511

Group type: EXPERIMENTAL
Intervention: High antihypertensive medication burden in the standard group
Number of subjects: 8511

Group type: EXPERIMENTAL
Intervention: High antihypertensive medication burden in the intensive group
Number of subjects: 8511
Study: 38600291

Group type: EXPERIMENTAL
Intervention: LOW-GI diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: LCHF diet
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIGH-GI diet
Number of subjects: 65
Study: 38600471

Group type: EXPERIMENTAL
Intervention: binimetinib 45 mg BID plus nivolumab 480 mg Q4W
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: binimetinib MTD/RP2D plus nivolumab and ipilimumab
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: binimetinib MTD/RP2D
Number of subjects: 75
Study: 38600496

Group type: EXPERIMENTAL
Intervention: Alerta Cannabis online intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 8
Study: 38600501

Group type: EXPERIMENTAL
Intervention: Pedicled buccal periosteal flap for closure of oroantral fistula
Number of subjects: 10
Study: 38600507

Group type: EXPERIMENTAL
Intervention: GFH018 5-85 mg BID (14d-on/14d-off)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GFH018 85 mg BID (7d-on/7d-off)
Number of subjects: 50
Study: 38600533

Group type: EXPERIMENTAL
Intervention: ACTIVA BioACTIVE
Number of subjects: 96

Group type: COMPARATOR
Intervention: Compomer (Dyract® eXtra)
Number of subjects: 96
Study: 38600541

Group type: EXPERIMENTAL
Intervention: Videoendoscopic radical inguinal lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open radical inguinal lymphadenectomy
Number of subjects: 0
Study: 38600571

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (low-intensity intervention plus funding for a hospital HBOT champion and regular practice facilitation sessions with an expert hub)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-intensity intervention (distribution of an HBOT best-practice manual, a lecture series based on the manual, referral to publicly available resources, and on-demand technical assistance)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-intensity intervention
Number of subjects: 24
Study: 38600583

Group type: EXPERIMENTAL
Intervention: Paclitaxel-hyaluronan conjugate ONCOFID-P-B™
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline biopsies analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intra-tumoral macrophage density and CD44v6 expression
Number of subjects: 20
Study: 38600599

Group type: EXPERIMENTAL
Intervention: CPT medication management intervention during hospitalization with follow-up post-discharge and communication with circle of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38600915

Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer (FET)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Fresh embryo transfer (fresh-ET)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Natural conception (NC)
Number of subjects: 606
Study: 38601063

Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE (100 mCi x 4 cycles)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Subsequent infusions of Lu-177-DOTATATE (reduced doses)
Number of subjects: 1
Study: 38601147

Group type: EXPERIMENTAL
Intervention: HLA mismatched co-transplantation of living donor kidney and facilitating cell-enriched HSCT
Number of subjects: 32

Group type: COMPARATOR
Intervention: On-IS (immunosuppression maintained)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 molecular mismatches
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-permissive HLA-DPB1 T-cell epitope group MM, HLA-B leader sequence, and KIR ligands MM
Number of subjects: 32
Study: 38601276

Group type: EXPERIMENTAL
Intervention: Islet or pancreas transplantation (β-cell Tx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38601485

Group type: EXPERIMENTAL
Intervention: utidelone (40 mg/m2)
Number of subjects: 26
Study: 38601720

Group type: EXPERIMENTAL
Intervention: Pulsed Electric Field (PEF) treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Durvalumab (immune checkpoint blockade)
Number of subjects: 1
Study: 38601830

Group type: EXPERIMENTAL
Intervention: Clavulanic Acid (CLAV) 500 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 13
Study: 38602105

Group type: EXPERIMENTAL
Intervention: SherpaPak (n=149)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Traditional cold storage (n=178)
Number of subjects: 327
Study: 38602417

Group type: EXPERIMENTAL
Intervention: KIN-3248 (5 to 50 mg orally daily)
Number of subjects: 54
Study: 38602618

Group type: EXPERIMENTAL
Intervention: Premixed group (group M): 12 mg of hyperbaric bupivacaine, 20 mcg of fentanyl, and 100 mcg of morphine injected as a single mixture.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Separate injection group (group S): Same drugs in separate injections.
Number of subjects: 126
Study: 38602658

Group type: EXPERIMENTAL
Intervention: Integrated self-management behaviors (including CGM usage, frequent glucose testing, insulin pump usage, carbohydrate counting application, adjustment of insulin doses, and usage of apps for diabetes management)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Each 1-unit increase in total behavior score
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM) usage
Number of subjects: 904
Study: 38602692

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS) with pharyngeal-sparing radiotherapy (PSRT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS) with unilateral neck RT (UNRT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pharyngeal-sparing radiotherapy (PSRT)
Number of subjects: 32
Study: 38602770

Group type: EXPERIMENTAL
Intervention: Digital therapeutics (DTx) mindfulness-based intervention (MBI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Attention-matched comparator intervention (math game)
Number of subjects: 70
Study: 38602780

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38602809

Group type: EXPERIMENTAL
Intervention: Considering one's legacy after receiving a serious and terminal cancer diagnosis
Number of subjects: 0
Study: 38603646

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 287

Group type: COMPARATOR
Intervention: Liposomal Daunorubicin
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 287
Study: 38603720

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccine regimen
Number of subjects: 367

Group type: COMPARATOR
Intervention: Participants with at least one positive helminth ELISA test result
Number of subjects: 367
Study: 38603800

Group type: EXPERIMENTAL
Intervention: Darvadstrocel treatment
Number of subjects: 73
Study: 38603973

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: DHA and AA
Number of subjects: 183
Study: 38604209

Group type: EXPERIMENTAL
Intervention: Coronary sinus reducer (CSR)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 38604213

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention plus optimal medical therapy
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 1606
Study: 38604212

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided percutaneous coronary intervention
Number of subjects: 3505

Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention
Number of subjects: 3505
Study: 38604297

Group type: EXPERIMENTAL
Intervention: CADe system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CADe-assisted workflow
Number of subjects: 30
Study: 38604496

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Duloxetine + Patient education
Number of subjects: 212

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 212

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 212
Study: 38604504

Group type: EXPERIMENTAL
Intervention: 1.4 g/kg/d protein emphasizing unprocessed lean beef (high protein experimental group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 1.4 g/kg/d protein from mixed food sources (high protein control)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.8 g total protein/kg body weight/day from mixed food sources (normal protein control)
Number of subjects: 49
Study: 38604769

Group type: EXPERIMENTAL
Intervention: Moderate Acute Malnutrition (MAM)
Number of subjects: 6692

Group type: EXPERIMENTAL
Intervention: Some/severe dehydration
Number of subjects: 6692

Group type: EXPERIMENTAL
Intervention: Both MAM and some/severe dehydration
Number of subjects: 6692
Study: 38604815

Group type: EXPERIMENTAL
Intervention: GS-4224 (400-1,500 mg once daily)
Number of subjects: 0
Study: 38605017

Group type: EXPERIMENTAL
Intervention: Repetitive audio-visual stimulation (flicker)
Number of subjects: 0
Study: 38605166

Group type: EXPERIMENTAL
Intervention: FPM-guided therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard therapy (previous therapy)
Number of subjects: 25
Study: 38605233

Group type: EXPERIMENTAL
Intervention: High glycemic index meal consumed in the evening (8 p.m.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High glycemic index meal consumed in the morning (7 a.m.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High glycemic index meal consumed in the morning or evening
Number of subjects: 45
Study: 38605328

Group type: EXPERIMENTAL
Intervention: Multi-component sedentary behavior reduction intervention (biweekly remote health coaching, wearable activity monitor, height-adjustable workstation, private Facebook group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 51
Study: 38605342

Group type: EXPERIMENTAL
Intervention: Narrow learning objectives and structured debriefing
Number of subjects: 32
Study: 38605350

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (Active group)
Number of subjects: 3936
Study: 38605374

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation during the post-operative period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38605396

Group type: EXPERIMENTAL
Intervention: Blood flow restriction training combined with IASTM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional ankle strength training
Number of subjects: 30
Study: 38605404

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia (BPD)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: BPD
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Structural and functional lung phenotyping
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Machine learning techniques
Number of subjects: 530
Study: 38605438

Group type: EXPERIMENTAL
Intervention: Routine screening for plasma BKPyV-DNAemia loads monthly until month 9, then every 3 months until 2 years post-transplant (3 years for children)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine cytology screening at similar time points to exclude BKPyV-nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of immunosuppression for patients with BKPyV-DNAemia loads >1000 copies/mL or exceeding 10,000 copies/mL, or with biopsy-proven BKPyV-nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of allograft biopsy for children with persisting BKPyV-DNAemia even without graft dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for diagnosing biopsy-proven BKPyV-nephropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kidney retransplantation subsequent to BKPyV-nephropathy if BKPyV-DNAemia is undetectable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine graft nephrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells)
Number of subjects: 0
Study: 38605470

Group type: EXPERIMENTAL
Intervention: Systematic screening for all manifestations of APECED syndrome
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NK cell lymphopenia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anti-interferon-α antibodies
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anti-interleukin-22 antibodies
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anti-interleukin-17F antibodies
Number of subjects: 25
Study: 38605658

Group type: EXPERIMENTAL
Intervention: High dose of psilocybin (25 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 38605958

Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8 weeks (Arm 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8, 12 weeks (Arm 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BVAC-C injection at 0, 4, 8, 12 weeks with topotecan at 2, 6, 10, 14 weeks (Arm 3)
Number of subjects: 30